LUCENTIS (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
LUCENTIS
Date registered
Evaluation commenced
Decision date
Approval time
196 working days (255)
Active ingredients
ranibizumab (rbe)
Registration type
EOI
Indication
LUCENTIS (solution for injection) is now also indicated in adults for the treatment of proliferative diabetic retinopathy (PDR).